BMS skin cancer vaccine hits phase III target
March 23, 2011Research and Development BMS, Bristol-Myers Squibb, advanced inoperable skin cancer, advanced melanoma, cancer drugs, cancer vaccine, ipilimumab
Bristol Myers Squibb’s cancer vaccine ipilimumab has increased overall survival in advanced melanoma patients. The therapy was being tested as …
Pharma manufacturing news in brief
March 22, 2011Manufacturing and Production American Regent, Berkshire Hathaway, Cytovance, Intercell, Solagran, West Pharmaceutical Services, morphosys, pharma contract manufacturing
Lubrizol bought for $9.7 billion by Berkshire Hathaway, plus the latest pharma manufacturing and quality news. Berkshire Hathaway, run by …
Novartis increases stake in Chinese vaccines firm
March 22, 2011Sales and Marketing China, emerging markets, vaccines
Novartis has continued its expansion into developing markets with the acquisition of a majority stake in a Chinese vaccines company. …
Roche’s skin cancer drug passes mid-stage trial
March 22, 2011Research and Development Curis, Roche, advanced basal cell carcinoma, skin cancer, vismodegib
Roche’s skin cancer candidate vismodegib has met its primary endpoint in a phase II trial. The drug is being tested …
Dendreon wins green light for Provenge production
March 22, 2011Manufacturing and Production Cancer, Dendreon, FDA, Provenge, pharma manufacturing, prostate cancer vaccine, sipuleucel-T
US oncology specialist Dendreon has been boosted by the approval of additional production capacity for its therapeutic prostate cancer vaccine …
Lonza wins two biomanufacturing contracts
March 22, 2011Manufacturing and Production Athera Biotechnologies, ENB-0040, Enobia Pharma, Lonza, PC-mAb, asfotase alfa, contract manufacturing, pharma, pharmaceuticals
Lonza has been awarded two contracts for biological drug candidates in quick succession, including a new deal that will make …
FDA and EMA join forces on quality-by-design
March 22, 2011Manufacturing and Production EMA, FDA, QbD, Quality by Design, pharmaceutical marketing applications
The FDA has teamed up with the EMA on a new pilot programme that will allow parallel evaluation of marketing …
Allergan marketing breaches discredited industry
March 22, 2011Medical Communications Allergan, Cephalon, PMCPA
Allergan, the manufacturer of Botox, has been censured for several breaches of the ABPI Code of Practice. The PMCPA watchdog …
Novartis gets FDA warning letter for Puerto Rico plant
March 21, 2011Manufacturing and Production Ciba Vision, FDA manufacturing inspections, Novartis, SoftPerm contact lenses, manufacturing compliance, pharma manufacturing
A manufacturing facility operated by Novartis subsidiary Ciba Vision in Puerto Rico has been cited for manufacturing quality violations and …
GSK Parkinson’s drug impresses at phase III
March 21, 2011Research and Development ADVANCE-PD, GSK, GlaxoSmithKline, IPX066, Impax Pharmaceuticals, Parkinson's disease, Parkinson’s disease
GlaxoSmithKline’s advanced Parkinson’s disease drug IPX066 has impressed in a head to head trial against it nearest rival. The phase …
Sanofi prostate cancer drug Jevtana approved in Europe
March 21, 2011Sales and Marketing Jevtana, Sanofi-Aventis, TROPIC clinical trial, cabazitaxel, cancer drugs, chemotherapy, prostate cancer
Sanofi-Aventis’ new chemotherapy treatment Jevtana has followed up on its US approval last year by receiving the green light in …
First oral MS pill approved in Europe
March 21, 2011Sales and Marketing MS, Novaris, fingolimod, first oral multiple sclerosis drug, gilenya, multiple sclerosis
Novartis’ Gilenya has become the first oral multiple sclerosis drug to be approved in Europe. Gilenya (fingolimod) is now licensed …
Guy Blomfield joins Alliance Medical Group
March 21, 2011Sales and Marketing appointment, sales and marketing
European diagnostic imaging company Alliance Medical Group has appointed Guy Blomfield as group chief operating officer. He joins from from …
Service Insight: Producing a better sales forecast
March 21, 2011Sales and Marketing Dr Hazel Rudge-Pickard, Pickard-Smith Consulting, Service Insight, forecasting
SERVICE INSIGHT
Financial Reporting – it’s all a foreign language… literally!
March 18, 2011Business Services Audits, Business, Financial, Languages, Reports, Services, TranslateMedia, tax, translation
Over the last two decades technology has allowed companies to greatly increase their global reach. Within the pharmaceutical sector it …
NHS Confederation: value-based pricing could increase NHS costs
March 18, 2011Sales and Marketing NHS Confederation, PPRS, Pharmaceutical Price Regulation Scheme, UK drug pricing, VBP, value-based pricing
Government plans to introduce value-based pricing in the UK could increase the NHS drugs bill without improving the effectiveness of …
Takeda obesity drug falters at phase II
March 18, 2011Research and Development Alli, Amylin, Contrave, Meridia, Qnexa, Takeda, Xenical, lorcaserin, metreleptin, obesity, pramlintide
Yet another investigational drug appears to have faltered on the rocky path to develop anti-obesity treatments. Takeda Pharmaceutical Company and …
GSK in manufacturing research collaboration with university
March 18, 2011Manufacturing and Production Advanced Manufacturing, Centre for Innovative Manufacturing in Emergent Macromolecular Therapies, EPSRC fund, GSK, GlaxoSmithKline, Manufacturing Fellowships, academic research, pharma manufacturing
Research into a cutting-edge area of pharmaceutical manufacturing in the UK is to be supported by a new £51 million …
Richard Bergström takes DG role at EFPIA
March 18, 2011Research and Development, Sales and Marketing Brian Ager, EFPIA, Richard Bergstrom, appointment, research and development, sales and marketing
European pharma industry association EFPIA has appointed Richard Bergström as its new director general. He takes over from Brian Ager, …
Novartis plans Q2 filing for blood cancer drug
March 17, 2011Sales and Marketing COMFORT-II trial, INC424, Incyte, JAK, Janus kinase inhibitor, Novartis, blood cancer, cancer drug, myelofibrosis, ruxolitinib
Novartis will file ruxolitinib for worldwide regulatory approval in the second quarter after the cancer drug met its primary endpoint …
Latest content
Scots neonatal innovations target hearing loss and earlier care
Agentis Health Group acquires Clinical Pharmacist Solutions
